Autolus Therapeutics plc (Nasdaq: AUTL), a biopharmaceutical company focused on T cell therapies, announced updated long-term data from the FELIX study of obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The data, which includes follow-up of up to approximately three years, will be presented at the European Hematology Association (EHA) Congress in Milan, Italy, from June 12-15, 2025. The study reports a median duration of response of 42.6 months, with over half of patients remaining in remission at 24 months. Additionally, 38% of ongoing responders did not require subsequent therapy by month 33, suggesting that a portion of patients may not need further treatment after receiving obe-cel. The presentation will cover factors associated with sustained remission and survival, including Philadelphia chromosome-positive status and ongoing CAR T-cell persistence.